KR950702970A - 사람 면역결필 바이러스(HIV) 역전사효소의 억제제로서의 벤족사지논(Benzoxazinones as inhibitors of HIV reverse transcriptase) - Google Patents

사람 면역결필 바이러스(HIV) 역전사효소의 억제제로서의 벤족사지논(Benzoxazinones as inhibitors of HIV reverse transcriptase) Download PDF

Info

Publication number
KR950702970A
KR950702970A KR1019950700472A KR19950700472A KR950702970A KR 950702970 A KR950702970 A KR 950702970A KR 1019950700472 A KR1019950700472 A KR 1019950700472A KR 19950700472 A KR19950700472 A KR 19950700472A KR 950702970 A KR950702970 A KR 950702970A
Authority
KR
South Korea
Prior art keywords
unsubstituted
compound
hiv
formula
chloro
Prior art date
Application number
KR1019950700472A
Other languages
English (en)
Other versions
KR100272387B1 (ko
Inventor
디. 영 스티븐
에프. 브릿쳐 수잔
에스. 페인 린다
오. 트란 레칸
씨. 룸마 2세 윌리암
Original Assignee
죠셉 에프. 디프리마
머크 앤드 캄파니, 인코포레이티드(Merck ＆ Co., Inc.)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26733517&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR950702970(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 죠셉 에프. 디프리마, 머크 앤드 캄파니, 인코포레이티드(Merck ＆ Co., Inc.) filed Critical 죠셉 에프. 디프리마
Publication of KR950702970A publication Critical patent/KR950702970A/ko
Application granted granted Critical
Publication of KR100272387B1 publication Critical patent/KR100272387B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heat Sensitive Colour Forming Recording (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

본 발명은, 기타 항 바이러스제, 면역조절제, 항생제 또는 백신과의 배합물이거나 또는 아니든지 간에, 화합물, 약제학적으로 허용되는 염 및 약제학적 조성물 성분중 어느 하나로서, HIV 역전사효소(이의 내성 변이체를 포함한)의 억제, HIV에 의한 감염의 예방 또는 치료 및 AIDS의 치료에 유용한 일반식(I)의 특정 벤조사지논에 관한 것이다.
상기식에서, X는 할로이고, X1은 트리할로메틸이거나 펜타할로에틸이고, Z는 0이다. 본 발명은 또한 AIDS치료 방법 및 HIV에 의한 감염의 예방 또는 치료 방법에 관한 것이다.

Description

사람 면역결핍 바이러스(HIV) 역전사효소의 억제제로서의 벤족사지논(Benzoxazinones as inhibitors of HIV reverse transcriptase)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (12)

  1. 일반식(I)의 화합물 또는 약제학적으로 허용되는 이의 염.
    상기식에서, X는 할로이고, X1은 트리할로메틸 또는 펜타할로에틸이며, Z는 0이고; R은 (a) 비치환되거나 A에 의해 치환된 C1-8알킬(여기서는, A는 할로, C3-8사이클로알킬, CN, 하이드록시, C1-4알콕시, C2-4알키닐-C1-4알콕시, 아릴옥시, C1-4알킬카보닐, 니트로, 디(C1-2알킬) 아미노, C1-4알킬아미노-C1-2알킬, 헤테로사이클 또는 아킬티오이다) 이거나; (b) 비치환되거나 (i) A 또는 (ii) 비치환되거나 또는 A에 의해 치환된 아릴에 의해 치환된 C2-4알케닐이거나; (c) 비치환되거나 (i) A 또는 (ii) 비치환되거나 또는 A에 의해 치환된 아릴에 의해 치환된 C2-5아키닐이거나; 또는 (d) 비치환되거나 (i) A 또는 (ii) 비치환되거나 또는 A에 의해 치환된 아릴에 의해 치환된 C3-4사이클로 알킬이다.
  2. 유효량의 일반식(II)의 화합물 또는 약제학적으로 허용되는 이의 염 및 약제학적으로 허용되는 담체를 포함하는, HIV 역전사를 억제하는데 유용한 약제학적 조성물.
    상기식에서, X는 할로이고, X1은 트리할로메틸; 펜타할로에틸; C2-5알킬; C2-5알키닐; C3-5사이클로알킬 또는 아릴이며, Z는 0 또는 S이고; R은 (a) 비치환되거나 A에 의해 치환된 C1-8알킬(여기에서, A는 할로, C3-6사이클로알킬, CN, 하이드록시, C1-4알콕시, C2-4알키닐 -C1-4알콕시, 아릴옥시, C1-4알킬카보닐, 니트로, 디(C1-2알킬)아미노, C1-4알킬아미노-C1-2알킬, 헤테로사이클 또는 아릴티오이다) 이거나; (b) 비치환되거나 (i) A 또는 (ii) 비치환되거나 또는 A에 의해 치환된 아릴에 의해 치환된 C2-4, 알케닐이거나; (c) 비치환되거나 (i) A 또는 (ii) 비치환되거나 또는 A에 의해 치환된 아릴에 의해 치환된 C2-5알키닐이거나; 또는 (d) 비치환되거나 (i) A 또는 (ii) 비치환되거나 또는 A에 의해 치환된 아릴에 의해 치환된 C3-4사이클로알킬이다.
  3. (-) 6-클로로-4-사이클로프로필에티닐-4-트리플루오로메틸-1,4-디하이드로-2H-3,1-벤족사진-2-온, (-) 6-클로로-4-페닐에티닐-4-트리플루오로메틸-1,4-디하이드로-2H-3,1-벤족사진-2-온 (+/-) 6-클로로-4-(2-시아노페닐)에티닐-4-(1,1,1-트리플루오로메틸)-1,4-디하이드로-2H-3,1-벤족사진-2-온, (+/-)4-(1-클로로-1,1-디플루오로메틸)-4-(2-페닐에티닐)-6-클로로-1,4-디하이드로-2H-3,1-벤족사진-2-온 또는 (+/-) 4-(2-[디메틸아미노메틸]에티닐)-4-트리플루오로메틸-6-클로로-1,4-디하이드로-2H-3,1-벤족사진-2-온인 화합물, 또는 약제학적으로 허용되는 이의 염.
  4. 포유동물에게 유효량의 일반식(I) 또는 (II)의 화합물 또는 제3항에 따른 화합물을 투여함을 포함하여, HIV 역전사효소를 억제시키는 방법.
  5. 포유동물에게 유효량의 일반식(I) 또는 (II)의 화합물 또는 제3항에 따른 화합물을 투여함을 포함하여, HIV의 감염을 예방하거나, HIV에 의한 감염을 치료하거나, 또는 AIDS 또는 ARC를 치료하는 방법.
  6. 유효량의 제1항, 제2항 또는 제3항에 따른 화합물 및 약제학적으로 허용되는 담체를 포함하는, HIV 역전사효소를 억제시키는데 유용한 약제학적 조성물.
  7. 유효량의 일반식(I) 또는 일반식(II)의 화합물 또는 제3항에 따른 화합물 및 약제학적으로 허용되는 담체를 포함하는 HIV 감염의 예방 또는 치료, 또는 AIDS 또는 ARC의 치료에 유용한 약제학적 조성물.
  8. HIV 역전사효소에 대해 생물학적활성을 갖는 뉴클레오사이드 동족체와 일반식(I) 또는 일반식(II)의 화합물의 배합물.
  9. L-743,726 및 L-735,524인 AIDS 항바이러스 화합물과 임의로, L-697,661, AZT, ddI 또는 ddC로 구성된 그룹으로부터 선택된 하나 이상의 HIV 억제제로 구성된 상승작용성 배합물.
  10. L-743,726인 AIDS 항바이러스 화합물과 L-697,661, AZT, ddI 또는 ddC로 구성된 그룹으로부터 선택된 하나 이상의 HIV 억제제로 구성된 상승작용성 배합물.
  11. (a) 일정량의 (+/-)-6-클로로-4-사이클로플필에티닐-4-트리플루오로메틸-1,4-디하이드로-2H-3,1-벤족사진-2-온(L-741,211)을 제공하는 단계; (b) 단계(a)의 화합물을 분해제와 축합시키는 단계; (c) 생성된 부분입체이성체를 분리시키는 단계; 및 (d) 분해제 개질물을 제거하여 목적하는 화합물을 수득하는 단계들을 포함하여, (-)-6-클로로-4-사이클로프로필에티닐-4-트리플루오로메틸-1,4-디하이드로-2H-3,1-벤족사진-2-온(L-743,726)을 합성하는 방법.
  12. 제11항에 있어서, 분해제가 (-)-캄파닐 클로라이드인 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950700472A 1992-08-07 1993-08-06 벤족사지논 화합물 및 이를 포함하는 사람 면역결핍 바이러스 역전사 효소 억제용 약제학적 조성물 KR100272387B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US92660792A 1992-08-07 1992-08-07
US7/926607 1992-08-07
US07/926,607 1992-08-07
US5480593A 1993-04-27 1993-04-27
US8/054,805 1993-04-27
US08/054,805 1993-04-27
PCT/US1993/007376 WO1994003440A1 (en) 1992-08-07 1993-08-06 Benzoxazinones as inhibitors of hiv reverse transcriptase

Publications (2)

Publication Number Publication Date
KR950702970A true KR950702970A (ko) 1995-08-23
KR100272387B1 KR100272387B1 (ko) 2000-11-15

Family

ID=26733517

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950700472A KR100272387B1 (ko) 1992-08-07 1993-08-06 벤족사지논 화합물 및 이를 포함하는 사람 면역결핍 바이러스 역전사 효소 억제용 약제학적 조성물

Country Status (37)

Country Link
EP (1) EP0582455B1 (ko)
JP (1) JPH0780860B2 (ko)
KR (1) KR100272387B1 (ko)
CN (3) CN1318031C (ko)
AT (1) ATE197295T1 (ko)
AU (1) AU670300B2 (ko)
BG (1) BG62612B1 (ko)
CA (1) CA2101572C (ko)
CZ (1) CZ290447B6 (ko)
DE (4) DE10199013I1 (ko)
DK (1) DK0582455T3 (ko)
DZ (1) DZ1707A1 (ko)
ES (1) ES2151897T3 (ko)
FI (1) FI115457B (ko)
GR (1) GR3034754T3 (ko)
HK (1) HK1009267A1 (ko)
HR (1) HRP931102B1 (ko)
HU (1) HU223076B1 (ko)
IL (1) IL106507A (ko)
LU (2) LU90709I2 (ko)
LV (1) LV12719B (ko)
MX (1) MX192812B (ko)
MY (1) MY109834A (ko)
NL (2) NL300032I2 (ko)
NO (3) NO304886B1 (ko)
NZ (1) NZ255216A (ko)
PL (2) PL175615B1 (ko)
PT (1) PT582455E (ko)
RO (1) RO113641B1 (ko)
RU (1) RU2186775C2 (ko)
SG (1) SG52698A1 (ko)
SI (1) SI9300419B (ko)
SK (1) SK282276B6 (ko)
TW (2) TWI233436B (ko)
UA (1) UA42699C2 (ko)
WO (1) WO1994003440A1 (ko)
YU (1) YU49439B (ko)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633405A (en) * 1995-05-25 1997-05-27 Merck & Co., Inc. Asymmetric synthesis of (-)-6-chloro-4-cyclopropyl-ethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxanzin-2-one
US6147210A (en) * 1996-07-26 2000-11-14 Dupont Pharmaceuticals Company Practical synthesis of benzoxazinones useful as HIV reverse transcriptase inhibitors
WO1998004535A1 (en) * 1996-07-26 1998-02-05 Du Pont Pharmaceuticals Company A practical synthesis of benzoxazinones useful as hiv reverse transcriptase inhibitors
US5932726A (en) * 1996-12-16 1999-08-03 Dupont Pharmaceuticals Company Asymmetric synthesis of benzoxazinones
ZA9711256B (en) 1996-12-16 1999-06-15 Du Pont Merck Pharma Asymmetric synthesis of benzoxazinones
PL197740B1 (pl) * 1997-02-05 2008-04-30 Merck & Co Inc Postać krystaliczna I (-)-6-chloro-4-cyklopropyloetynylo-4-trifluorometylo-1,4-dihydro-2H-3,1-benzoksazyn-2-onu i sposób krystalizacji postaci I (-)-6-chloro-4-cyklopropylo-etynylo-4-trifluorometylo-1,4-dihydro-2H-3,1-benzoksazyn-2-onu
US5965729A (en) 1997-02-05 1999-10-12 Merck & Co., Inc. Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
CA2285000A1 (en) * 1997-04-07 1998-10-15 Dupont Pharmaceuticals Company Asymmetric synthesis of benzoxazinones via new intermediates
US6124302A (en) 1997-04-09 2000-09-26 Dupont Pharmaceuticals 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones useful as HIV reverse transcriptase inhibitors
US5952528A (en) * 1997-09-03 1999-09-14 Merck & Co., Inc. Process for enhancing the optical purity
JP4157272B2 (ja) * 1997-09-03 2008-10-01 メルク エンド カムパニー インコーポレーテッド ２ｒ−［１−ヒドロキシ−１−トリフルオロメチル−３−シクロプロピルプロピン−２−イル］−４−クロロアニリンの光学純度を高める方法
US20010014352A1 (en) 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
HRP990182A2 (en) * 1998-06-11 2000-02-29 Du Pont Pharm Co Crystalline efavirenz
US6673372B1 (en) 1998-06-11 2004-01-06 Bristol-Myers Squibb Pharma Company Crystalline Efavirenz
EP1091939A1 (en) * 1998-06-30 2001-04-18 Du Pont Pharmaceuticals Company Substituted quinolin-2(1h)-ones useful as hiv reverse transcriptase inhibitors
SE9904652D0 (sv) * 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
WO2002081456A1 (en) 2001-03-28 2002-10-17 Bristol-Myers Squibb Company Cyanamide, alkoxyamino, and urea derivatives of 4, 4-disubstituted-3, 4-dihydro-2 (1h)- quinazolinones as hiv reverse transcriptase inhibitors
EP1608629A1 (en) 2003-03-24 2005-12-28 F. Hoffmann-La Roche Ag Benzyl-pyridazinons as reverse transcriptase inhibitors
ES2549084T3 (es) * 2007-10-05 2015-10-22 Msd K.K. Derivados de benzoxazinona
GB0720503D0 (en) 2007-10-22 2007-11-28 Angeletti P Ist Richerche Bio New compound
EP2448917A2 (de) 2009-07-03 2012-05-09 Archimica GmbH Verfahren zur enantioselektiven addition von organometallischen kohlenstoffnukleophilen an trifluormethylketone und verwendung des verfahrens in der synthese von hiv reverse transcriptase inhibitoren
KR20170078868A (ko) 2010-01-27 2017-07-07 비이브 헬쓰케어 컴퍼니 항바이러스 치료
EP2471783A1 (en) 2010-12-23 2012-07-04 Esteve Química, S.A. Novel polymorphic form of efavirenz
CN103664816B (zh) * 2011-01-06 2016-03-02 中国科学院上海有机化学研究所 Hiv逆转录酶抑制剂依法韦伦类化合物的一锅法不对称合成工艺
CN102675125B (zh) * 2011-03-15 2015-02-18 中国科学院上海有机化学研究所 一种4-氯-2-三氟乙酰基苯胺及其类似物的简便高效合成方法
JP7071036B2 (ja) 2019-02-15 2022-05-18 福建永晶科技股▲ふん▼有限公司 Ｆｒｉｅｄｅｌ－Ｃｒａｆｔｓ反応の新しい新方法及び当該方法に用いられる触媒
CN110372625B (zh) * 2019-08-06 2022-11-01 常州大学 蓝光照射制备4-烷甲基-4-芳基-1,3-苯并噁嗪-2(4h)-酮的方法
CN113106473B (zh) * 2021-04-14 2022-02-18 南京工业大学 一种通过连续电化学微反应器装置制备1,3-苯并噁嗪衍生物的方法
WO2023064196A1 (en) * 2021-10-15 2023-04-20 Merck Sharp & Dohme Llc Benzoxazinone derivatives as selective cytotoxic agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3526621A (en) * 1966-08-03 1970-09-01 Farmaceutical Italia Soc Substituted 3,1-benzoxazin-2-one
US3562621A (en) * 1967-07-26 1971-02-09 Technipower Inc Inrush current limiting circuit for rectifier circuits with capacitive load
DE3217012A1 (de) * 1982-05-06 1983-11-10 Dr. Karl Thomae Gmbh, 7950 Biberach Benzoxazin-2-one, deren herstellung und diese verbindungen enthaltende arzneimittel
CA2032259A1 (en) * 1989-12-18 1991-06-19 Wayne J. Thompson Hiv protease inhibitors useful for the treatment of aids
IL99843A0 (en) * 1990-11-01 1992-08-18 Merck & Co Inc Synergistic combination of hiv reverse transcriptase inhibitors

Also Published As

Publication number Publication date
YU53093A (sh) 1996-10-09
ES2151897T3 (es) 2001-01-16
HRP931102B1 (en) 2001-06-30
LV12719A (lv) 2001-09-20
DE69329608D1 (de) 2000-12-07
BG62612B1 (bg) 2000-03-31
JPH06184124A (ja) 1994-07-05
NZ255216A (en) 1996-05-28
AU4449693A (en) 1994-02-10
NO2008008I1 (no) 2008-06-30
CN1318031C (zh) 2007-05-30
CA2101572A1 (en) 1994-02-08
CN1250652A (zh) 2000-04-19
NO950424D0 (no) 1995-02-06
EP0582455B1 (en) 2000-11-02
WO1994003440A1 (en) 1994-02-17
LV12719B (lv) 2001-12-20
DE10199013I1 (de) 2001-05-23
JPH0780860B2 (ja) 1995-08-30
DZ1707A1 (fr) 2002-02-17
IL106507A0 (en) 1993-11-15
FI950508A0 (fi) 1995-02-06
NO2000004I1 (no) 2000-06-16
CN1090277A (zh) 1994-08-03
RU2186775C2 (ru) 2002-08-10
HRP931102A2 (en) 1997-10-31
SG52698A1 (en) 1998-09-28
MX192812B (es) 1999-07-30
CA2101572C (en) 2001-08-28
KR100272387B1 (ko) 2000-11-15
CN1107505C (zh) 2003-05-07
YU49439B (sh) 2006-03-03
CN1221608A (zh) 1999-07-07
TW382014B (en) 2000-02-11
DE122008000034I1 (de) 2008-10-02
DE10199013I2 (de) 2007-05-24
LU90709I2 (fr) 2002-02-04
BG99383A (bg) 1995-09-29
FI115457B (fi) 2005-05-13
GR3034754T3 (en) 2001-02-28
HUT71219A (en) 1995-11-28
SI9300419A (en) 1994-06-30
PL176679B1 (pl) 1999-07-30
HU223076B1 (hu) 2004-03-01
MX9304775A (es) 1994-05-31
DE69329608T2 (de) 2001-05-03
IL106507A (en) 1997-11-20
RO113641B1 (ro) 1998-09-30
CZ290447B6 (cs) 2002-07-17
UA42699C2 (uk) 2001-11-15
RU95107403A (ru) 1996-11-20
SK16195A3 (en) 1995-07-11
SI9300419B (sl) 2002-10-31
SK282276B6 (sk) 2002-01-07
ATE197295T1 (de) 2000-11-15
NL300347I1 (nl) 2008-07-01
AU670300B2 (en) 1996-07-11
FI950508A (fi) 1995-02-06
NL300032I1 (ko) 2001-02-01
CN1051767C (zh) 2000-04-26
MY109834A (en) 1997-08-30
PT582455E (pt) 2001-03-30
EP0582455A1 (en) 1994-02-09
NO950424L (no) 1995-04-06
NO304886B1 (no) 1999-03-01
CZ28695A3 (en) 1995-09-13
HU9500366D0 (en) 1995-03-28
PL175615B1 (pl) 1999-01-29
LU91446I2 (fr) 2008-07-28
TWI233436B (en) 2005-06-01
PL307348A1 (en) 1995-05-15
DK0582455T3 (da) 2000-11-27
HK1009267A1 (en) 1999-05-28
NL300032I2 (nl) 2001-04-02

Similar Documents

Publication Publication Date Title
KR950702970A (ko) 사람 면역결필 바이러스(HIV) 역전사효소의 억제제로서의 벤족사지논(Benzoxazinones as inhibitors of HIV reverse transcriptase)
BRPI0515896A (pt) composto ou um sal ou éster farmaceuticamente aceitável do mesmo, método para o tratamento ou profilaxia de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus, e, composição farmacêutica para o tratamento de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus
WO2006083553A3 (en) Diketo acids with nucleobase scaffolds: anti-hiv replication inhibitors targeted at hiv integrase
DE69629195D1 (de) Inhibitor von gehirnödemen
MX9302681A (es) Nuevas quinazolinas como inhibidores de transcriptasa inversa hiv.
KR970704441A (ko) 사람 면역결핍증 바이러스 프로테아제 억제제 배합물(HIV Protease inhibitor combination)
KR900002787A (ko) 인체 후천성 면역부전증후군 바이러스 감염 저해제
KR910009260A (ko) 퀴놀릴- 및 이소퀴놀릴옥사졸- 2- 온의 당단백질 외막 바이러스 감염 치료 용도

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20120727

Year of fee payment: 13

EXPY Expiration of term